IGC Pharma, Inc.·5

May 15, 4:11 PM ET

PRINS RICHARD K 5

5 · IGC Pharma, Inc. · Filed May 15, 2025

Insider Transaction Report

Form 5
Period: 2025-03-31
Transactions
  • Exercise/Conversion

    Common Stock

    2025-03-31+58,3331,101,251 total
  • Exercise/Conversion

    Common Stock

    2025-03-31+100,0001,201,251 total
  • Exercise/Conversion

    Common Stock

    2025-03-31+70,0001,271,251 total
  • Exercise/Conversion

    Restricted Stock Units

    2025-03-3158,3330 total
    Common Stock (58,333 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2025-03-31100,000100,000 total
    Common Stock (100,000 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2025-03-3170,000140,000 total
    Common Stock (70,000 underlying)
Footnotes (4)
  • [F1]On May 25, 2022, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 31, 2023.
  • [F2]On June 20, 2023, the Reporting Person was granted RSUs subject to vesting equally over three years starting on March 31, 2024.
  • [F3]On March 13, 2024, the Reporting Person was granted RSUs subject to vesting equally over three years starting March 2025.
  • [F4]Each restricted stock unit represents a right to receive one share of IGC common stock.

Documents

1 file
  • 5
    ownership.xmlPrimary